enfr+33 (0)5 17 81 07 63contact@meccellis.com

News

News

SFCD

France • Marne-La-Vallée • New York hotel
November 22nd – 24th, 2023

19th congress of digestive hepatic-biliopancreatic surgery.

INTERNATIONAL EXPERT MEETING

Swiss – Geneva University Hospitals
October 20th, 2023

Outlet obstruction: Functional and anatomical disorder.

abstract biological mesh for rectopexy

ABSTRACT

Europe PubMed Central
septembre, 2023

“Moving from Laparoscopic synthetic mesh to robotic biological mesh for ventral rectopexy : Results from case Series”

LONDON BREAST MEETING

London • Royal College of Physicians
September 07th – 09th, 2023

News in Oncological, Reconstructive and Aesthetic Breast Surgery.

PELVEX MEETING 2023

Cité du Vin in Bordeaux, FRANCE
June 29th and 30th, 2023

The congress brings together international specialized members in complex pelvic surgeries.

BARCELONA BREAST MEETING

Barcelona Breast Meeting – Hospital Sant Pau
March 22nd – 24th, 2023

Reconstructive and Aesthetic Breast Surgery.

LONDON BREAST MEETING

London – Royal College of Physicians
September 08th – 10th, 2022

News in Oncological, Reconstructive and Aesthetic Breast Surgery.

LOOKING FOR NEW PARTNERS

Meccellis Biotech
March 16th, 2022

Meccellis biotech is looking for new partners to distribute our biological matrix for Breast reconstruction, Cellis® Breast.

Guillaume Hofmanski interviewed by Sophie De Menthon on C News

CNews

CNews “Patrons in Questions”
February 06th, 2024

Guillaume Hofmanski, general manager of Meccellis Biotech, interviewed by Sophie de Menthon on CNews

Fundraising

Group Ph Tech (Meccellis Biotech, Apha Biomat) is delighted to announce that we’ve raised €5m in Series B funding, led by the continued participation of Océan Participations with the participations of new investors Volney Développement, Synergence BA and co-investor Fonds NACO (M CAPITAL).

Alongside with Bpifrance, Région Nouvelle-Aquitaine, Territoires d’industrie, European Union, the support of all investors will allow us to offer innovative solutions for tomorrow’s surgeries.

This financing round is also supported by the future development of Meccellis Biotech on US market, leading to a total operation of €8m.

This is a major milestone for our rapidly growing Group Ph Tech, and a signal to the market that Apha Biomat‘s medical devices will soon be available.

We are honoured by the presence of PIERRICK CHARROT, FABIEN POIRIER, AMAURY CAMBON, GILLES GANTOIS in Ph Tech’s board.

© 2024 Meccellis. All right reserved.